<DOC>
	<DOC>NCT01135797</DOC>
	<brief_summary>The objective of this study is to collect retrospectively long term safety data in patients who have participated in the previous phase I-II trials conducted with the compound.</brief_summary>
	<brief_title>Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Inclusion criteria: Patient randomized, treated and alive at the end of the phase III study participation, irrespective of their treatment group, Who signed the TALISMAN survey informed consent (or for deceased patients, the informed consent was signed the legal representative/family member as per national regulations except in countries where Ethics Committee approval only is required for retrospective data collection). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>